hnRNPC facilitates coronavirus replication by directly binding the frameshift-stimulatory element of viral genomic RNA.

hnRNPC facilitates coronavirus replication by directly binding the frameshift-stimulatory element of viral genomic RNA.

Publication date: Aug 01, 2026

Translation of key viral replicative proteins in coronaviruses requires a programmed -1 ribosomal frameshifting (-1 PRF) event controlled by the viral frameshift-stimulatory element (FSE). Although previous studies have analyzed host factor dependencies of coronaviruses, how host cellular factors alter -1 PRF efficiency and affect viral replication remains poorly understood. Here, using RNA pull-down combined with LC-MS/MS analysis, we identified heterogeneous nuclear ribonucleoprotein C (hnRNPC) as a major interacting protein of FSE RNA. Coronavirus infection triggers hnRNPC mRNA decay, alters hnRNPC protein levels, and induces its cytoplasmic relocalization, where it appears to bind directly to FSE RNA through residues Asn7 and Asn83. This binding is associated with increased -1 PRF efficiency and may facilitate coronavirus replication. Deletion mapping analysis shows that hnRNPC preferentially binds U-rich regions of the FSE RNA. Finally, we demonstrated that the small molecule Elbasvir directly binds hnRNPC, disrupting the interaction between hnRNPC and FSE RNA and inhibiting coronavirus replication by decreasing -1 PRF efficiency. Collectively, our study identifies hnRNPC as a key host cofactor for coronaviruses and provides a novel target for broad-spectrum antiviral drug development.

Open Access PDF

Concepts Keywords
Antiviral Animals
Coronaviruses Coronavirus
Efficiency Coronavirus Infections
Host Frameshifting, Ribosomal
Ribosomal Genome, Viral
Humans
RNA, Viral
RNA, Viral
Virus Replication

Semantics

Type Source Name
pathway REACTOME Translation
pathway KEGG Viral replication
disease MESH Coronavirus infection
drug DRUGBANK Elbasvir
drug DRUGBANK ANX-510
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH COVID 19 pandemic
drug DRUGBANK Trestolone
pathway KEGG Ribosome
drug DRUGBANK Zinc
disease MESH syndrome
drug DRUGBANK Amino acids
pathway REACTOME mRNA Splicing
disease MESH infection
drug DRUGBANK Tetrahydrofolic acid
disease MESH tumor
disease MESH viral infections
drug DRUGBANK Aspartame
drug DRUGBANK Uridine
drug DRUGBANK Dactinomycin
pathway REACTOME M Phase
disease MESH hpi
disease MESH dis
disease MESH NLS
drug DRUGBANK Methyl isocyanate
disease MESH image
drug DRUGBANK Deferoxamine
drug DRUGBANK Pralatrexate
drug DRUGBANK Montelukast
disease MESH heart disease
disease MESH CAM
drug DRUGBANK Indoleacetic acid
pathway REACTOME Metabolism
disease MESH hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
disease MESH FBS
disease MESH strains
drug DRUGBANK Urea
drug DRUGBANK Trypsin
pathway REACTOME Digestion
disease MESH PBS
drug DRUGBANK Benzamidine
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
drug DRUGBANK Tromethamine
disease MESH Rad
drug DRUGBANK Albendazole
disease MESH glass
drug DRUGBANK L-Leucine
drug DRUGBANK Gold
drug DRUGBANK Sulfate ion
drug DRUGBANK Bean
drug DRUGBANK Trinitrotoluene
drug DRUGBANK Methionine
drug DRUGBANK Water
disease MESH Severe acute respiratory syndrome
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH pneumonia
disease MESH Dengue
disease MESH AS1
disease MESH Lung Cancer
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH Influenza
drug DRUGBANK Myricetin
drug DRUGBANK Lurasidone
disease MESH hepatitis
disease MESH NS1
drug DRUGBANK Carboxyamidotriazole
disease MESH metastasis
pathway REACTOME Autophagy
drug DRUGBANK Urokinase
pathway REACTOME Glycolysis
disease MESH squamous carcinoma
disease MESH Death
disease MESH Non Alcoholic Fatty Liver Disease

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *